LGND Q4 2021 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

LGNDLigand Pharmaceuticals Incorporated

$4B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$72M+3.5% YoY

Gross Profit

$60M83.5% margin

Operating Income

$13M17.6% margin

Net Income

-$5M-7.5% margin

EPS (Diluted)

$-0.30

QoQ Revenue Growth

+11.8%

Cash Flow

Operating Cash Flow

$28M

Free Cash Flow

$25M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$476M

Stockholders' Equity

$821M

Cash & Equivalents

$20M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$72M	$70M	+3.5%
Gross Profit	$60M	$58M	+3.8%
Operating Income	$13M	$11M	+13.6%
Net Income	-$5M	$6M	-194.0%

Revenue Segments

Material Sales, Captisol

$35M39%

Contract Revenue

$20M22%

Royalty

$18M19%

Milestone

$9M10%

Royalty, Other

$6M6%

License Fees

$3M3%